New eye drops aim to soothe dry eyes in patients with nerve disorders

NCT ID NCT07566975

Recruiting now Symptom relief Sponsor: Neuro-Ophthalmology of Texas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing VEVYE eye drops (cyclosporine 0.1%) in 50 adults with dry eye disease who also have a neuro-ophthalmic condition, such as neurotrophic keratitis. Participants use the drops twice daily for 6 months. Researchers will measure changes in corneal staining and symptom scores to see if the drops improve signs and symptoms of dry eye in this specific patient group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclosporine ophthalmic solution 0.1% (VEVYE)
What this could lead to: If successful, this could show that VEVYE is a safe and effective short-term option for managing dry eye in people with neuro-ophthalmic conditions.
What could go wrong: This is a small, early observational study with no control group, so results may not be conclusive. It only looks at short-term effects and may not apply to all dry eye patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE

Contacts and locations

Locations

Neuro Ophthalmology of TX
RECRUITING

Houston, Texas, 77074, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.